

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/269049 A1

(51) International Patent Classification:

C07D 213/42 (2006.01) C07D 471/04 (2006.01)
C07D 231/12 (2006.01) A61K 31/4412 (2006.01)
C07D 239/26 (2006.01) A61P 25/20 (2006.01)
C07D 307/94 (2006.01) A61P 43/00 (2006.01)
C07D 401/04 (2006.01)

(21) International Application Number:

PCT/EP2022/067376

(22) International Filing Date:

24 June 2022 (24.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/215,054 25 June 2021 (25.06.2021) US

(71) Applicant: **JAZZ PHARMACEUTICALS IRELAND LIMITED** [IE/IE]; Waterloo Exchange, Waterloo Road, Dublin, 4 (IE).

(72) Inventor; and

(71) Applicant: **MARINELLI, Davide** [IT/IE]; c/o Jazz Pharmaceuticals Ireland Limited, Waterloo Exchange, Waterloo Road, Dublin, 4 (IE).

(72) Inventors: **CHOVATIA, Prafulkumar**; c/o Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB). **BEATO, Claudia**; c/o Aptuit (Verona) SRL, Via A. Fleming 4, 37135 Verona (IT). **OU-VRY, Gilles**; c/o Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB).

(74) Agent: **COOLEY (UK) LLP**; 22 Bishopsgate, London EC2N 4BQ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,


CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF



(57) Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, A, L₁, L₂, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a disease or disorder that is treatable by administration of an Orexin agonist.

WO 2022/269049 A1